Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities

Chronic Venous Disease Clinical Trial

— SuloPrima  

Official title:

Efficacy and Safety of Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities: A Randomized Placebo-Controlled Double-Blind Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05005052
• Other study ID #: 2021-002311-64
• Status: Recruiting
• Phase: Phase 3
• Start date: November 25, 2021
• Est. completion date: December 2023

Study information

• Verified date: June 2023
• Source: Value Outcomes Ltd.
• Contact: Jan Tužil
• Phone: 00420727824059
• Email: jan.tuzil[@]valueoutcomes.cz
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study compares the efficacy and safety of sulodexide (Vessel) to placebo in patients with chronic venous disease of the lower extremities.

The primary hypothesis is that more patients will achieve a decrease in rVCSS score of at least 4 points with sulodexide than with placebo.

Description:

Chronic venous disease (CVD) prevalence is increasing in developed countries. The frequency reported in different sources ranges between 10 and 50% of the population and its rise is expected resulting from the overall aging of the population. The most common symptoms of Chronic venous disease of lower extremities include, increased limb fatigue, heaviness and swelling, pain, cramps, itching, and trophic skin changes that can result in a venous ulcer. CVD has a significant impact on the patient's quality of life and their work productivity.

Conservative treatment consists of lifestyle measures, compression therapy and use of venoactive drugs (venopharmaceuticals). Venoactive drugs are a heterogenous group of compounds with various mechanisms of action, such as increasing venous wall tonus, reducing capillary fragility and permeability, increasing capillary resistance, and improving lymphatic drainage. The goal of the treatment is anti-oedematous action, improvement of trophism of affected tissues, reduction of subjective symptoms, swelling of the limbs and affecting related trophic skin changes which leads to the increase of quality of life.

Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy. The aim of the present study is to provide the first high-level (causal) evidence on the efficacy and safety of sulodexide across the whole spectrum of patients suffering from symptomatic primary CVD (CEAP classification C2S to C6S).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 290
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed primary venous disease of the lower limbs in stage C2 - C6 according to the CEAP classification, clinical involvement of the venous system of the lower limbs is verified by duplex ultrasonography

• Presence of objective and subjective symptoms of the disease (classified according to rVCSS score = 4)

• At the time of the enrolment, patient is not using nor planning to use compression therapy from his own decision or the decision of the treating physician

• The patient signed an informed consent for inclusion in the clinical trial and consent to the processing of personal data

• Patient over 18 years of age

• Male or female patient of non-childbearing potential, i.e.: post-menopausal (at least 2 years without spontaneous menses) or surgically sterile (bilateral tubal occlusion or hysterectomy or ablation of both ovaries); OR of childbearing potential but with a negative pregnancy test result at Visit 1 AND agrees to use a highly effective method of contraception

Exclusion Criteria:

• Use of a drug with venoactive effect in the last month

• Regular use of compression therapy or use of mechanical devices for reduction of oedema in the last month

• Heart Failure as per NYHA III and IV, congestive heart failure with peripheral oedemas

• Chronic kidney disease with GF < 30 ml/min (< 0,5 ml/s) and/or proteinuria > 0,5 g/24 hours, nephrotic syndrome, renal oedemas

• Advanced liver disease (Child-Pugh B and C or laboratory values of ALT or AST more than 3 times upper limit of normal range)

• Deep venous thrombosis lower limb thrombosis and / or documented residual venous obstruction or deep venous reflux due to post-thrombotic changes in the deep venous system

• Superficial venous thrombosis of the lower limbs in the previous 6 months

• Congenital venous / venolymphatic venous malformation

• Neuropathy of any aetiology

• Diabetic foot syndrome

• Refractory (uncontrollable) arterial hypertension (inability to achieve therapeutically systolic blood pressure = 160 mmHg or diastolic blood pressure = 100 mmHg)

• Symptomatic ischemic disease of lower limbs

• Lymphoedema: primary, posttraumatic, postoperative, post-radiation, malignant

• Manual/instrumental lymphatic drainage in the last 6 months

• Invasive procedure on the lower limbs in the last 6 months

• Trauma of the lower extremity that has not fully healed

• Use of oral/parenteral anticoagulants, dual antiplatelet therapy, diuretics, corticosteroids, oestrogens, or progesterone and its derivates

• Chronic pain treatment = 14 days

• Psychopharmaceuticals affecting fluid retention (antipsychotics, combined antidepressants)

• Pathologic obesity (BMI > 40 kg/m2)

• The patient is currently enrolled in another interventional or non-interventional study

• Contraindications to the administration of sulodexide according to IB (haemorrhagic diathesis, hypersensitivity to the drug substance or any of the excipients, heparin, heparinoids or other glycosaminoglycans (GAGs), etc.)

• Patients with active malignant disease or malignant disease in remission for less than 5 years

• Pregnancy

• Breastfeeding

Continuous exclusion criteria:

• Clinically significant progression of the investigated condition, which requires urgent or early invasive therapy (as assessed by the investigating physician)

• Onset of any condition requiring initiation of the not permitted medication/treatment

• Serious adverse reactions

• Pregnancy

Compression therapy can be initiated anytime during the trial participation in case that patient experiences worsening of the rVCSS score of at least 4 points compared to baseline AND the treating physician decides to prescribe such regimen. Certified/notified compression stockings of class II (23-32 mmHg) based on circular knit are allowed. Patients initiating compression therapy are not excluded but the stocking need to be taken off a day before the scheduled study visit. The treatment allocation in patients initiating compression therapy remain blinded.

In case compression therapy is initiated during study participation, information about the date of initiation, type and adherence is collected in the following visits.

If sufficient proportion of subjects is switched to compression therapy, compression therapy will be tested as effect modifier across CEAP classes.

Related Conditions & MeSH terms

• Chronic Venous Disease
• Venous Insufficiency

Intervention

Drug:
• Vessel
Sulodexide has protective effect on the endothelium, antithrombotic, fibrinolytic and anti-inflammatory effects. In the last 20 years, it has been well established in the common practice and its efficacy and safety have been demonstrated notably in the treatment of venous diseases such as post-thrombotic syndrome of the lower extremities, secondary prevention of deep and superficial venous thrombosis, supportive treatment of leg venous ulceration, ischemic disease of the lower limbs; symptomatic therapy of intermittent claudication, treatment of diabetic ulcers and microcirculation disorders of various aetiology. Patients with CVD were shown to respond quickly to sulodexide therapy in single arm observational studies. Sulodexide seems to provide both symptomatic and causal therapy.
• Placebo
Placebo and no compression or venopharmaceutical regimen

Locations

Country	Name	City	State
Czechia	Cor et Vasa s.r.o	Ceský Tešín	Moravskoslezský Kraj
Czechia	Angiologická ambulance s.r.o.	Hlucín	Moravskoslezský Kraj
Czechia	CTC Hodonín s.r.o.	Hodonín	Jihomoravský Kraj
Czechia	CardioVasc s.r.o.	Mladá Boleslav	Stredoceský Kraj
Czechia	Oblastní nemocnice Mladá Boleslav, a.s.	Mladá Boleslav	Stredoceský Kraj
Czechia	Cordesora s.r.o.	Olomouc	Olomoucký Kraj
Czechia	Angiologie Opava s.r.o.	Opava	Moravskoslezský Kraj
Czechia	Chirurgická ambulance MUDr. Prokop	Ostrava	Moravskoslezský Kraj
Czechia	Péce o cévy s.r.o.	Ostrava	Moravskoslezský Kraj
Czechia	Pedicor s.r.o.	Ostrava	Moravskoslezský Kraj
Czechia	Žilní klinika	Prague
Czechia	Cévní ambulance - Poliklinika Modrany	Prague
Czechia	MUDr.Simon Jirát s.r.o. - Angiologie Zbraslav	Prague
Czechia	FLEBODERMA, s.r.o.	Praha
Czechia	MUDr. Jan KVASNICKA,CSc., Ordinace pro choroby srdce a cév	Praha
Czechia	REAGINTA sro	Prerov	Olomoucký Kraj
Czechia	Angios s.r.o.	Prostejov	Olomoucký Kraj
Czechia	Phlebomedica s.r.o.	Rícany	Stredoceský Kraj
Czechia	Angionika s.r.o.	Slaný	Stredoceský Kraj

Sponsors (2)

Lead Sponsor	Collaborator
Value Outcomes Ltd.	Alfasigma S.p.A.

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Revised Venous Clinical Severity Score (rVCSS)	A minimal decrease in rVCSS score by 4 points will be considered a clinically significant response to treatment.	24 weeks of treatment
Secondary	Revised Venous Clinical Severity Score (rVCSS)	A minimal decrease in rVCSS score by 4 points will be considered a clinically significant response to treatment.	4, 8 and 12 weeks of treatment
Secondary	Volume in lower limb	The decrease of lower limb volume of at least 30 mL will be determined using water displacement leg volumetry and will be considered a clinically significant response to treatment.	4, 8, 12 and 24 weeks of treatment
Secondary	Visual Analogue Scale (VAS)	Decrease in mean pain on Visual Analogue Scale.	4, 8, 12 and 24 weeks of treatment
Secondary	Work Productivity and Activity Impairment (WPAI questionnaire)	Increase in mean work productivity in WPAI questionnaire.	8 and 24 weeks of treatment
Secondary	EQ-5D questionnaire	Increase in the mean generic quality of life in EQ-5D questionnaire.	8 and 24 weeks of treatment
Secondary	Chronic Venous Insufficiency Quality of Life (CIVIQ-20 questionnaire)	Increase in the mean disease-specific quality of life in CIVIQ-20 questionnaire.	8 and 24 weeks of treatment
Secondary	Mean time of clinically significant worsening rVCSS	Mean time of worsening the rVCSS score since study initiation of at least 4 points. The difference will be visualized using Kaplan-Meier estimates and tested using Cox proportional-hazards models.	4, 8, 12 and 24 weeks of treatment
Secondary	Compression therapy initiation	Mean time of duration of initiation of compression therapy since study initiation. The difference will be visualized using Kaplan-Meier estimates and tested using Cox proportional-hazards models.	4, 8, 12 and 24 weeks of treatment